Icu Medical (ICUI) 88.98 $ICUI
Shares of ICUI Up 42.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 11, 9:19AM CST
SmarTrend identified an Uptrend for ICU Medical (NASDAQ:ICUI) on August 12th, 2014 at $62.20. In approximately 6 months, ICU Medical has returned 42.09% as of today's recent price of $88.38.
ICUI: 88.98 (+0.42)
ICU's (ICUI) CEO Vivek Jain on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 7:06PM CST
ICUI: 88.98 (+0.42)
ICU Medical posts 4Q profit
Automated Insights - Mon Feb 09, 4:58PM CST
SAN CLEMENTE, Calif. (AP) _ ICU Medical Inc. (ICUI) on Monday reported fourth-quarter net income of $7.4 million.
ICUI: 88.98 (+0.42)
Medtronic's Pipeline Flex Embolization Device Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:05PM CST
Medtronic announced the FDA approval for its Pipeline Flex embolization device (the next-generation flow diversion device).
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)
ICU Medical (ICUI) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Feb 09, 3:25PM CST
ICUI: 88.98 (+0.42)
ICU Medical beats by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:18PM CST
ICUI: 88.98 (+0.42)
ICU Medical, Inc. Announces Fourth Quarter and Fiscal Year 2014 Results
GlobeNewswire - Mon Feb 09, 3:11PM CST
ICU Medical, Inc., (Nasdaq:ICUI) ("ICU Medical"
, a leader in innovative medical devices used in vascular therapy, oncology and critical care applications, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014.
ICUI: 88.98 (+0.42)
U.S. Market for Infusion Therapy Devices 2015 (Executive Summary)
M2 - Mon Feb 09, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jtjsm/u_s_market_for) has announced the addition of the "U.S. Market for Infusion Therapy Devices 2015 (Executive Summary)" report to their offering. This market includes infusion pumps, intravenous (IV) sets, and needleless connectors (NLCs). The infusion pump market is further divided into segments for large volume, syringe, patient-controlled analgesia (PCA), electronic ambulatory and disposable ambulatory infusion pumps. Main Markets Covered: - Infusion Pump Market - Intravenous Set Market - Needleless Connector Market - Anti-reflux neutral displacement needleless connectors Companies Mentioned - B. Braun - Baxter International - Carefusion - Hospira - ICU Medical - Smiths Medical For more information visit http://www.researchandmarkets.com/research/3j...market_for
ICUI: 88.98 (+0.42), BAX: 70.39 (+0.31)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Feb 08, 4:35PM CST
CCK: 50.65 (+0.74), MXL: 8.37 (+0.09), TDW: 30.01 (+1.45), MOH: 59.66 (+0.26), DAC: 5.86 (-0.01), PRI: 55.09 (+0.55), ICUI: 88.98 (+0.42), NEWP: 20.29 (-0.01), CSC: 66.10 (+1.60), GSM: 15.60 (+0.06), QLYS: 47.95 (+1.46), AMAG: 41.49 (+0.23), AMKR: 8.90 (-0.02), NTES: 112.99 (-0.49), IPHI: 19.17 (-1.48), GIG: 1.19 (+0.05), ALSN: 31.88 (+0.24), KS: 32.52 (-0.35), SSNI: 9.15 (+0.36), CMP: 91.66 (+0.52), COUP: 11.06 (-0.07), MRH: 36.05 (-0.54), NBIX: 37.22 (+0.27), MODN: 11.64 (-0.01), RLD: 12.65 (+0.16), DNB: 133.27 (+0.46), WCN: 46.05 (-0.42), MCC: 9.44 (+0.15), CRK: 6.09 (+0.46), OTTR: 31.27 (unch), MERU: 2.74 (-0.01)
CareFusion Q2 Earnings & Revenues Top Estimates, Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:22AM CST
CareFusion Corporation's (CFN) second-quarter fiscal 2015 EPS surged nearly 83.3% on a year-over-year basis driven by strong revenue growth.
ICUI: 88.98 (+0.42), BDX: 143.71 (+0.72), ABAX: 60.93 (+0.65), CFN: 59.81 (+0.01)
U.S. Market for Infusion Therapy Devices 2015
M2 - Fri Feb 06, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/l949rj/u_s_market_for) has announced the addition of the "U.S. Market for Infusion Therapy Devices 2015" report to their offering. The infusion therapy device market was disrupted by product recalls affecting a significant proportion of installed base units. However, newer pump systems that incorporate additional features, such as wireless capabilities and drug libraries, will enhance patient safety and drive growth in the market. Unit sales of premium-priced pump systems will contribute to overall growth in the infusion therapy device market. The segments comprising the infusion therapy device market experienced differing growth rates in 2014. A determining factor for growth rates was the increasing emphasis on patient safety. As a result, ASPs for infusion pumps will increase as manufacturers incorporate more sophisticated software that allows practitioners to administer the correct dosage and medication to the right patient. Integration with electronic medical records (EMRs) and wireless capabilities are important drivers in the infusion pump market. However, healthcare expenditure reductions have led to a decline in hospitals beds and a shift towards non-acute settings. Sales of IV sets and needleless connectors remain a significant source of revenues for companies that are able to rely on their presence in the infusion pump market to sell related accessories. While the ASP for a pump is significantly higher than for an IV set or a connector, a pump is a one-time purchase. Recent experience with recalls has illustrated the challenges associated with maintaining a large installed base of pumps. The needleless connector market is heavily dependent on clinical results and practitioner preference. Problems associated with positive displacement devices have led to a trend towards the increasing use of neutral displacement devices, which is expected to persist over the forecast period. Key Topics Covered: List Of Figures List Of Charts 1. Executive Summary 2. Research Methodology 3. U.S. Infusion Therapy Device Market Overview 4. Infusion Pump Market 5. Intravenous Set Market 6. Needleless Connector Market Companies Mentioned - B. Braun - Baxter International - Carefusion - Hospira - ICU Medical - Smiths Medical For more information visit http://www.researchandmarkets.com/research/l9...market_for
ICUI: 88.98 (+0.42), BAX: 70.39 (+0.31)
Boston Scientific Tops Q4 Earnings, Revenues Miss Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 9:27AM CST
Boston Scientific (BSX) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 22 cents in the fourth quarter of 2014.
BSX: 14.98 (+0.24), ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), ABAX: 60.93 (+0.65)
ICU Medical Shares Up 33.4% Since SmarTrend's Buy Recommendation (ICUI)
Comtex SmarTrend(R) - Tue Feb 03, 5:11PM CST
SmarTrend identified an Uptrend for ICU Medical (NASDAQ:ICUI) on August 12th, 2014 at $62.20. In approximately 6 months, ICU Medical has returned 33.41% as of today's recent price of $82.98.
ICUI: 88.98 (+0.42)
Haemonetics Q3 Earnings Top Estimates, Drop Y/Y; Stock Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 9:00AM CST
Although Haemonetics' (HAE) earnings topped the Zacks Consensus Estimate, it reflected a significant slash year-over-year. With the bleak performance of blood center as well as hospital disposable businesses, the top line too failed to meet our expectation
ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), ABAX: 60.93 (+0.65), HAE: 42.94 (-0.59)
Abaxis (ABAX) Beats Q3 Earnings, Revenues; Margin Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 12:50PM CST
Based on an encouraging top line, Abaxis' (ABAX) fiscal third-quarter gross profit rose 51% to $29.2 million
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), ABAX: 60.93 (+0.65), HSIC: 143.18 (+0.72)
Haemonetics (HAE) in Focus: Stock Adds 6.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 8:25AM CST
Haemonetics (HAE) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 88.98 (+0.42), HAE: 42.94 (-0.59)
Baxter (BAX) Beats Q4 Earnings Estimates, Sales Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:20PM CST
Baxter International Inc (BAX) reported fourth-quarter 2014 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 3 cents.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
Mead Johnson's US Expansion Drives Q4 Earnings Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 10:09AM CST
Mead Johnson (MJN) achieved positive sales growth in two of its three segments, while sales growth in Asia was not up to the mark owing to Mead Johnson's weak performance in China.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), MJN: 101.89 (+2.32), PAHC: 30.85 (+0.36)
St. Jude Q4 Earnings Meet Estimates on Modest Sales Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 11:30AM CST
St. Jude Medical Inc (STJ) reported adjusted EPS of $1.03, which was in line with the Zacks Consensus Estimate.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), PAHC: 30.85 (+0.36), STJ: 67.48 (+0.65)
Stryker Lags Q4 Earnings, Revenue Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 7:21AM CST
Stryker Corp (SYK) reported disappointing fourth-quarter 2014 financial numbers.
ICUI: 88.98 (+0.42), SNN: 35.82 (-0.28), NXTM: 17.56 (-0.05), SYK: 94.51 (+1.14)
Shares of ICUI Up 42.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 11, 9:19AM CST
SmarTrend identified an Uptrend for ICU Medical (NASDAQ:ICUI) on August 12th, 2014 at $62.20. In approximately 6 months, ICU Medical has returned 42.09% as of today's recent price of $88.38.
ICUI: 88.98 (+0.42)
ICU's (ICUI) CEO Vivek Jain on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 7:06PM CST
ICUI: 88.98 (+0.42)
ICU Medical posts 4Q profit
Automated Insights - Mon Feb 09, 4:58PM CST
SAN CLEMENTE, Calif. (AP) _ ICU Medical Inc. (ICUI) on Monday reported fourth-quarter net income of $7.4 million.
ICUI: 88.98 (+0.42)
Medtronic's Pipeline Flex Embolization Device Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 09, 4:05PM CST
Medtronic announced the FDA approval for its Pipeline Flex embolization device (the next-generation flow diversion device).
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)
ICU Medical (ICUI) Q4 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Feb 09, 3:25PM CST
ICUI: 88.98 (+0.42)
ICU Medical beats by $0.09, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:18PM CST
ICUI: 88.98 (+0.42)
ICU Medical, Inc. Announces Fourth Quarter and Fiscal Year 2014 Results
GlobeNewswire - Mon Feb 09, 3:11PM CST
ICU Medical, Inc., (Nasdaq:ICUI) ("ICU Medical"
, a leader in innovative medical devices used in vascular therapy, oncology and critical care applications, today announced financial results for the fourth quarter and fiscal year ended December 31, 2014. ICUI: 88.98 (+0.42)
U.S. Market for Infusion Therapy Devices 2015 (Executive Summary)
M2 - Mon Feb 09, 9:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jtjsm/u_s_market_for) has announced the addition of the "U.S. Market for Infusion Therapy Devices 2015 (Executive Summary)" report to their offering. This market includes infusion pumps, intravenous (IV) sets, and needleless connectors (NLCs). The infusion pump market is further divided into segments for large volume, syringe, patient-controlled analgesia (PCA), electronic ambulatory and disposable ambulatory infusion pumps. Main Markets Covered: - Infusion Pump Market - Intravenous Set Market - Needleless Connector Market - Anti-reflux neutral displacement needleless connectors Companies Mentioned - B. Braun - Baxter International - Carefusion - Hospira - ICU Medical - Smiths Medical For more information visit http://www.researchandmarkets.com/research/3j...market_for
ICUI: 88.98 (+0.42), BAX: 70.39 (+0.31)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Feb 08, 4:35PM CST
CCK: 50.65 (+0.74), MXL: 8.37 (+0.09), TDW: 30.01 (+1.45), MOH: 59.66 (+0.26), DAC: 5.86 (-0.01), PRI: 55.09 (+0.55), ICUI: 88.98 (+0.42), NEWP: 20.29 (-0.01), CSC: 66.10 (+1.60), GSM: 15.60 (+0.06), QLYS: 47.95 (+1.46), AMAG: 41.49 (+0.23), AMKR: 8.90 (-0.02), NTES: 112.99 (-0.49), IPHI: 19.17 (-1.48), GIG: 1.19 (+0.05), ALSN: 31.88 (+0.24), KS: 32.52 (-0.35), SSNI: 9.15 (+0.36), CMP: 91.66 (+0.52), COUP: 11.06 (-0.07), MRH: 36.05 (-0.54), NBIX: 37.22 (+0.27), MODN: 11.64 (-0.01), RLD: 12.65 (+0.16), DNB: 133.27 (+0.46), WCN: 46.05 (-0.42), MCC: 9.44 (+0.15), CRK: 6.09 (+0.46), OTTR: 31.27 (unch), MERU: 2.74 (-0.01)
CareFusion Q2 Earnings & Revenues Top Estimates, Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:22AM CST
CareFusion Corporation's (CFN) second-quarter fiscal 2015 EPS surged nearly 83.3% on a year-over-year basis driven by strong revenue growth.
ICUI: 88.98 (+0.42), BDX: 143.71 (+0.72), ABAX: 60.93 (+0.65), CFN: 59.81 (+0.01)
U.S. Market for Infusion Therapy Devices 2015
M2 - Fri Feb 06, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/l949rj/u_s_market_for) has announced the addition of the "U.S. Market for Infusion Therapy Devices 2015" report to their offering. The infusion therapy device market was disrupted by product recalls affecting a significant proportion of installed base units. However, newer pump systems that incorporate additional features, such as wireless capabilities and drug libraries, will enhance patient safety and drive growth in the market. Unit sales of premium-priced pump systems will contribute to overall growth in the infusion therapy device market. The segments comprising the infusion therapy device market experienced differing growth rates in 2014. A determining factor for growth rates was the increasing emphasis on patient safety. As a result, ASPs for infusion pumps will increase as manufacturers incorporate more sophisticated software that allows practitioners to administer the correct dosage and medication to the right patient. Integration with electronic medical records (EMRs) and wireless capabilities are important drivers in the infusion pump market. However, healthcare expenditure reductions have led to a decline in hospitals beds and a shift towards non-acute settings. Sales of IV sets and needleless connectors remain a significant source of revenues for companies that are able to rely on their presence in the infusion pump market to sell related accessories. While the ASP for a pump is significantly higher than for an IV set or a connector, a pump is a one-time purchase. Recent experience with recalls has illustrated the challenges associated with maintaining a large installed base of pumps. The needleless connector market is heavily dependent on clinical results and practitioner preference. Problems associated with positive displacement devices have led to a trend towards the increasing use of neutral displacement devices, which is expected to persist over the forecast period. Key Topics Covered: List Of Figures List Of Charts 1. Executive Summary 2. Research Methodology 3. U.S. Infusion Therapy Device Market Overview 4. Infusion Pump Market 5. Intravenous Set Market 6. Needleless Connector Market Companies Mentioned - B. Braun - Baxter International - Carefusion - Hospira - ICU Medical - Smiths Medical For more information visit http://www.researchandmarkets.com/research/l9...market_for
ICUI: 88.98 (+0.42), BAX: 70.39 (+0.31)
Boston Scientific Tops Q4 Earnings, Revenues Miss Mark - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 9:27AM CST
Boston Scientific (BSX) reported adjusted earnings per share (EPS) (after considering certain one-time adjustments other than amortization expense) of 22 cents in the fourth quarter of 2014.
BSX: 14.98 (+0.24), ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), ABAX: 60.93 (+0.65)
ICU Medical Shares Up 33.4% Since SmarTrend's Buy Recommendation (ICUI)
Comtex SmarTrend(R) - Tue Feb 03, 5:11PM CST
SmarTrend identified an Uptrend for ICU Medical (NASDAQ:ICUI) on August 12th, 2014 at $62.20. In approximately 6 months, ICU Medical has returned 33.41% as of today's recent price of $82.98.
ICUI: 88.98 (+0.42)
Haemonetics Q3 Earnings Top Estimates, Drop Y/Y; Stock Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 02, 9:00AM CST
Although Haemonetics' (HAE) earnings topped the Zacks Consensus Estimate, it reflected a significant slash year-over-year. With the bleak performance of blood center as well as hospital disposable businesses, the top line too failed to meet our expectation
ICUI: 88.98 (+0.42), CSII: 35.69 (+0.17), ABAX: 60.93 (+0.65), HAE: 42.94 (-0.59)
Abaxis (ABAX) Beats Q3 Earnings, Revenues; Margin Grows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 12:50PM CST
Based on an encouraging top line, Abaxis' (ABAX) fiscal third-quarter gross profit rose 51% to $29.2 million
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), ABAX: 60.93 (+0.65), HSIC: 143.18 (+0.72)
Haemonetics (HAE) in Focus: Stock Adds 6.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 30, 8:25AM CST
Haemonetics (HAE) was a big mover last session, with shares rising nearly 7% on the day.
ICUI: 88.98 (+0.42), HAE: 42.94 (-0.59)
Baxter (BAX) Beats Q4 Earnings Estimates, Sales Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 4:20PM CST
Baxter International Inc (BAX) reported fourth-quarter 2014 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 3 cents.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), BAX: 70.39 (+0.31), NKTR: 13.54 (-0.14)
Mead Johnson's US Expansion Drives Q4 Earnings Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 29, 10:09AM CST
Mead Johnson (MJN) achieved positive sales growth in two of its three segments, while sales growth in Asia was not up to the mark owing to Mead Johnson's weak performance in China.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), MJN: 101.89 (+2.32), PAHC: 30.85 (+0.36)
St. Jude Q4 Earnings Meet Estimates on Modest Sales Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 11:30AM CST
St. Jude Medical Inc (STJ) reported adjusted EPS of $1.03, which was in line with the Zacks Consensus Estimate.
ICUI: 88.98 (+0.42), NXTM: 17.56 (-0.05), PAHC: 30.85 (+0.36), STJ: 67.48 (+0.65)
Stryker Lags Q4 Earnings, Revenue Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 28, 7:21AM CST
Stryker Corp (SYK) reported disappointing fourth-quarter 2014 financial numbers.
ICUI: 88.98 (+0.42), SNN: 35.82 (-0.28), NXTM: 17.56 (-0.05), SYK: 94.51 (+1.14)
